Immuron (IMRN) Income from Continuing Operations (2016 - 2024)
Immuron (IMRN) recorded quarterly Income from Continuing Operations of 1.6602591656689772e+18 in Q4 2024, up 80082653894884.78% quarter-over-quarter from 2073182.0 in Q4 2023, and up 80082653894884.8% on a YoY basis from N/an in Q1 2024.
Immuron (IMRN) Income from Continuing Operations (2016 - 2024) Analysis & Trends
Immuron's Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 1.6602591656689772e+18 for Q4 2024.
- In Q4 2024, Income from Continuing Operations rose 80082653894884.8% year-over-year to 1.6602591656689772e+18; the TTM figure through Dec 2024 stood at 1.6602591656656522e+18 (up 49735740978232.03% YoY), while the FY2025 annual figure was 3380634.04, up 25.69% from the prior year.
- Income from Continuing Operations was 1.6602591656689772e+18 for Q4 2024 at Immuron, up from 2073182.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1.6602591656689772e+18 in Q4 2024 to a low of 2073182.0 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 2.7670986094426358e+17 across 5 years, with a median of 35323.95 in 2020.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations tumbled 15849.51% in 2023, then jumped 80082653894884.8% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 57387.72 in 2020, then soared by 76.89% to 13260.17 in 2021, then climbed by 1.97% to 12998.41 in 2022, then sank by 15849.51% to 2073182.0 in 2023, then surged by 80082653894884.78% to 1.6602591656689772e+18 in 2024.
- The last three Income from Continuing Operations figures came in at 1.6602591656689772e+18 (Q4 2024), 2073182.0 (Q4 2023), and 1238720.54 (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Immuron | 921.61 Mn | 921.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1,660,259,165.67 Bn |
| Dec 31, 2023 | -2.07 Mn |
| Jun 30, 2023 | -1.24 Mn |
| Dec 31, 2022 | -12,998.41 |
| Dec 31, 2021 | -13,260.17 |
| Dec 31, 2020 | -57,387.72 |
| Dec 31, 2019 | -15,212.27 |
| Dec 31, 2018 | -1.58 Mn |
| Dec 31, 2017 | 3.84 Mn |
| Dec 31, 2016 | 2.56 Mn |
| Jun 30, 2016 | -3.28 Mn |